Myriad Genetics Advances Prostate Cancer Care with Addition of Absolute Risk Reduction to Prolaris®
15 Agosto 2023 - 8:05AM
Myriad Genetics, Inc., (NASDAQ: MYGN) a leader in genetic testing
and precision medicine, today announced the integration of Absolute
Risk Reduction (ARR) into the Prolaris® Prostate Cancer Prognostic
Test to help patients and providers make personalized treatment
decisions regarding hormone therapy. Prolaris is the only biomarker
test to quantify the benefits of adding androgen deprivation
therapy (ADT) to radiation therapy (RT)1.
ADT can be effective at slowing the progression of prostate
cancer, but it can also be associated with significant side effects
such as bone and muscle loss, weight gain and increased
cardiovascular risk. In addition to helping identify those patients
who can safely forego ADT, the latest Prolaris enhancement will now
provide patients with an individual assessment of how adding ADT to
radiation therapy may reduce their risk of metastasis over 10
years.
“When men are diagnosed with localized prostate cancer, they
have choices about different kinds of therapies. Often they’re
considering combining therapies together or just doing an
individual therapy,” said Dr. Jonathan Tward, MD, PhD, at the
Huntsman Cancer Institute at the University of Utah. “With the
Prolaris test physicians can now counsel patients on whether adding
ADT to their treatment plan may reduce their individualized risk of
metastasis. This offers increased clarity to make informed
decisions, balancing the potential side effects of ADT.”
At the 2023 American Society of Clinical Oncology Annual
Meeting, Dr. Tward presented a study that found Prolaris can
predict the ARR of metastasis when ADT is added to RT regardless of
National Comprehensive Cancer Network® risk group. When a patient’s
Prolaris results fell below the multi-modal treatment threshold,
adding ADT to RT resulted in an average ARR of 0.86%, implying
minimal benefits against potential side effects. However, for those
above the threshold, adding ADT to RT yielded an average ARR of
8.2%, indicating a more meaningful benefit from ADT that could
outweigh the possible side effects.
“Determining how much a patient benefits from ADT versus the
side effects is critical to making the best treatment decisions for
patients with prostate cancer,” said Terry White, General Manager
of Urology, Myriad Genetics. “With the addition of Absolute Risk
Reduction to the Prolaris report, patients and their providers can
have a more personalized risk-benefit discussion and decide on the
most effective treatment path.”
For more information about Prolaris, visit:
https://myriad.com/urology/understanding-the-prolaris-report/
About Myriad GeneticsMyriad Genetics is a
leading genetic testing and precision medicine company dedicated to
advancing health and well-being for all. Myriad develops and offers
genetic tests that help assess the risk of developing disease or
disease progression and guide treatment decisions across medical
specialties where genetic insights can significantly improve
patient care and lower healthcare costs. For more information,
visit www.myriad.com.
Safe Harbor StatementThis press release
contains “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995, including
statements relating to the addition of Absolute Risk Reduction to
Prolaris and that the addition of ARR will provide patients with an
individual assessment of how adding ADT to radiation therapy may
reduce their risk of metastasis over 10 years. These
“forward-looking statements” are management’s expectations of
future events as of the date hereof and are subject to known and
unknown risks and uncertainties that could cause actual results,
conditions, and events to differ materially and adversely from
those anticipated. Such factors include those risks described in
the company’s filings with the U.S. Securities and Exchange
Commission, including the company’s Annual Report on Form 10-K
filed on March 1, 2023, as well as any updates to those risk
factors filed from time to time in the company’s Quarterly Reports
on Form 10-Q or Current Reports on Form 8-K. Myriad is not under
any obligation, and it expressly disclaims any obligation, to
update or alter any forward-looking statements, whether as a result
of new information, future events or otherwise except as required
by law.
1 Tward JD, et al. Predicting Absolute Benefit in Risk of
Metastasis of Androgen Deprivation Therapy added to Radiation
Therapy in Patients with Newly Diagnosed Prostate Cancer. JCO 41,
no. 16_suppl (June 01, 2023)5030
Media
Contact: |
|
Investor Contact: |
Glenn Farrell |
|
Matt Scalo |
(385) 318-3718 |
|
(801) 584-3532 |
PR@myriad.com |
|
IR@myriad.com |
Myriad Genetics (NASDAQ:MYGN)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Myriad Genetics (NASDAQ:MYGN)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024